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ADMINISTRATIVE CLAIMS ANALYSIS OF PATIENTS WITH TYPE-2
DIABETES INITIATING SITAGLIPTIN THERAPY
Fabunmi R1, Wade R2, Quimbo RA3, Hou L3, Pawaskar MD4, Misurski D4
1Amylin Pharmaceuticals, Inc., San Diego, CA, USA, 2HealthCore, Inc., Wilmington, DC, USA, 
3HealthCore, Inc., Wilmington, DE, USA, 4Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: Clinical trials have reported A1C reductions of 0.7% over 24 weeks 
for sitagliptin monotherapy and when added to metformin (baseline A1C  8.0%
 for both). When added to pioglitazone the mean A1C reduction was 0.9% (baseline 
A1C  8.1%). With monotherapy 45% of patients achieved A1C  7.0%. METHODS:
Patient characteristics and real-world effectiveness of sitagliptin were investigated using
a large US claims database. Patients with new prescription claims for sitagliptin 
between 10/1/06 and 3/31/07 and q12 months pre- and post-index eligibility were 
included (n  3719). Mean (SD) age was 56.0 (o10.0) and 39% were female. Co-
morbidities included: hypertension (84%), dyslipidemia (83%), and other cardiovas-
cular disease (25%). The starting dose was 100 mg for 93% of patients. Concomitant
antihyperglycemic medications at index (100 to 15 days post index) included met-
formin (58%), thiazolidinediones (41%), sulfonylureas (37%) and insulin (16%).
Seven percent had no concomitant antihyperglycemic medications. RESULTS: The 
mean (SD) number of concomitant medications was 1.9 (o1.0). Insulin use increased
from 16% to 25% (p  .0001), in the 12 month post-index period. Other concomitant 
medications showed little change. The medication possession ratio (days supply/365
days) in patients with 1 prescription claim was 74 o 29%. Clinical effectiveness was
measured in patients with baseline (6 months pre-index – 1 month post index) and 
post-index (60–365 days) A1C data (n  102). Mean (SD) baseline A1C was 7.6%
(o1.0) with an absolute reduction of 0.2% (o1.1) [mean duration of follow-up  246.0
(o81.6) days]. Of 72 patients with a baseline A1C q7.0%, 21 (29%) achieved an A1C 
goal of 7.0%. CONCLUSIONS: This study reports real-world analyses of sitagliptin
patient characteristics and effectiveness. Adherence to therapy was similar to that for 
other oral antihyperglycemic drugs, but mean reduction in A1C and percent to goal 
were less than in clinical trials, despite an increase in the percent of patients using 
insulin.
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COMPARISON OF DOSING PATTERNS OF DULOXETINE AND 
PREGABALIN AMONG PATIENTS WITH DIABETIC PERIPHERAL
NEUROPATHIC PAIN
Sun P1, Zhao Y2, Bledsoe S2, Watson PR2
1Kailo Research Group, Indianapolis, IN, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To compare dosing patterns between duloxetine and pregabalin among 
patients with diabetic peripheral neuropathic pain (DPNP). METHODS: Using a large
administrative claims database in the United States, we examined commercially 
insured individuals aged 18–64 who dispensed duloxetine or pregabalin in 2006. The
date of the ﬁ rst duloxetine or pregabalin prescription dispensed was deﬁ ned as the
index date. All patients selected were diagnosed with DPNP and had continuous 
enrollment over the 12-month pre- index period. Each patient was classiﬁ ed in the 
duloxetine or pregabalin cohorts based on the index agent, and all duloxetine or pre-
gabalin prescriptions ﬁ lled over the 12-month follow-up period were examined. We 
compared the average daily dose of all prescriptions per person, average daily dose in 
each of the ﬁ rst 10 prescriptions, and percent of daily dose change from previous
prescription between duloxetine and pregabalin cohorts. RESULTS: Among 603 
duloxetine patients and 1751 pregabalin patients, the average daily doses of all pre-
scriptions were 51.2mg and 179.8mg for duloxetine and pregabalin, respectively. The
average daily doses for the 1st and 10th duloxetine scripts were 53.8mg (95% Conﬁ -
dence Interval (CI): 52.4, 55.2) and 64.9mg, while the numbers were 166mg (95%
CI: 162, 170) and 264.3mg (95% CI: 244.1, 284.4) for pregabalin. The changes in 
daily doses from previous prescription were 0.2–4.0% for duloxetine and 0.8–12.5%
for pregabalin, respectively. The percentage of change in daily dose from the 1st to 
10th prescription was signiﬁ cantly higher for pregabalin (59.2%) than for duloxetine
(20.7%) (p  0.05). CONCLUSIONS: DPNP patients on duloxetine or pregabalin 
experienced very different dosing patterns. The average daily dose for duloxetine was
relatively stable over time, while pregabalin patients had signiﬁ cant dose escalation
over the 12-month follow-up period.
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THE EFFECTS OF SUSTAINED-RELEASE GLIPIZIDE VERSUS GLICLAZIDE
FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF
RANDOMIZED CONTROLLED TRIALS
Wang L1, Li Y2
1Sichuan University, Chengdu, Sichuan, China, 2West China Hospital, Sichuan University, 
Chengdu, China
OBJECTIVES: There are currently many kinds of sulphonylurea agents taken as the 
ﬁ rst-line drugs for patients with diabetes. As the second-generation sulfonylureas, 
we try to explore the comparative efﬁ cacy and safety of sustained-release glipizide 
and gliclazide for type 2 diabetes mellitus. METHODS: A systematic review of ran-
domized controlled trials (RCTs) was conducted. PUBMED, EMBASE, The Cochrane 
Library, three Chinese Databases (CBM, CNKI, and VIP), as well as the citations or
reference lists were searched from their inception to July 31, 2008. The pharmaceutical 
companies were contacted for unpublished studies. Trial selection, quality assessment
and data extraction were performed by two reviewers independently. We pooled
the trial data using the random-effect model and explored the heterogeneity by the 
pre-speciﬁ ed variables. RESULTS: Only two trials (n  190) compared the extended-
release glipizide with gliclazide based on the treatment of metformin or acarbose and 
diet control. The quality of included trials was poor. Only randomized trials were
mentioned without detailed information on the methods of generating randomization 
sequences, concealment allocation, and blinding. The durations of follow-up(12 
weeks) were too short to obtain the long-term effects of the diabetes-related morbidity 
and mortality. Both sustained-release glipizide and gliclazide had signiﬁ cantly reduced 
HbA1c, fasting and postprandial blood glucose from baseline to the end of treatment. 
However, there was no signiﬁ cant difference between groups, including the changes
of HbA1c (weighted mean difference  0.13, 95%CI  0.21 to 0.46), fasting blood 
glucose (0.07 [0.67, 0.52]), and postprandial blood glucose (1.40 [0.80, 3.60]).
There is similar safe proﬁ les in hypoglycemia, changes of lipid and body weight, and 
liver and renal functions. CONCLUSIONS: The limited evidence showed that both 
sustained-release glipizide and gliclazide are effective in glucose control with similar
effects and safe proﬁ le. More high-quality RCTs are expected to explore the effects of 
different sulfonylurea agents.
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A COMPARISON OF ECONOMIC OUTCOMES BETWEEN ADHERENT 
AND NONADHERENT PATIENTS TREATED WITH ORAL ANTIDIABETIC
MEDICATIONS
Hansen RA1, Farley JF1, Droege M2, Maciejewski ML3
1University of North Carolina, Chapel Hill, NC, USA, 2Takeda Pharmaceuticals North 
America, Inc, Deerﬁ eld, IL, USA, 3Center for Health Services Research in Primary Care, 
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OBJECTIVES: Health care costs for adherent patients were compared with costs for 
nonadherent patients in a cohort with diabetes mellitus taking metformin, sulfonyl-
ureas, or pioglitazone. METHODS: Using both, the commercial and Medicare supple-
mental MEDSTAT MarketScan research databases, a retrospective cohort study 
identiﬁ ed 108,592 continuously insured patients 18 to 90 years of age with diabetes 
mellitus (ICD-9-CM 250.xx) using metformin, sulfonylureas, or pioglitazone mono-
therapy during 2003. Adherence was calculated in 2004 and 2005 using a medication
possession ratio, and dichotomized at q80% to indicate adherence. Total health care 
costs included insurer payments and patient cost-sharing from medical (inpatient, 
outpatient) and prescription drug claims. Diabetes-speciﬁ c costs included pharmacy 
claims for any diabetes drug and medical claims containing a primary diagnosis of 
diabetes or a diabetes complication. Multivariate analysis was conducted to adjust for 
potential confounders. RESULTS: During the initial year of follow-up, the proportion 
of patients adherent to treatment were 57%, 61%, and 59% for metformin, sulfonyl-
ureas, and pioglitazone, respectively. Annual unadjusted total health care costs were
consistently lower for adherent patients than for non-adherent patients ($1470 less 
for metformin users, $3734 less for sulfonylurea users, and $3477 for pioglitazone 
users). In the multivariate models, total health care costs and diabetes speciﬁ c health 
care costs respectively were $846 (95% CI $747 to $945) and $55 (95% CI $33 to 
$77) per year lower for adherent patients compared to nonadherent patients. The 
adjusted annual adherence-related cost difference was $336 for metformin (95% CI
$216 to $456), $1509 for sulfonylureas (95% CI $1339 to $1679), and $1,140 for 
pioglitazone (95% CI $793 to $1486). Annual cost differences were larger among 
Medicare plans compared with commercial insurance plans ($2220 lower vs $65 
higher, respectively). CONCLUSIONS: Adherence with oral diabetes medications
results in overall health care cost-savings. Both sulfonylureas and pioglitazone were
associated with larger total cost-savings than metformin.
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EFFECT OF ACE INHIBITORS AND ARBS ON INCIDENCE OF RENAL
DISEASE IN ELDERLY PATIENTS WITH DIABETES
Yadav R1, Agarwal SJ1, Desai R1, Chitnis A1, Morgan R2, Johnson M1, Chen H1
1University of Houston, Houston, TX, USA, 2University of Texas, Houston, TX, USA
OBJECTIVES: To examine the association of Angiotensin Converting Enzyme inhibi-
tors (ACEI) and Angiotensin Receptor Blockers (ARBs) with Diabetes Nephropathy
or Chronic Renal Failure (DN/CRF), in patients with age 65 years or more with dia-
betes mellitus. METHODS: The study was a retrospective cohort study on elderly 
diabetic patients in the Veteran Affairs (VA). Exposure to ACEI and ARBs was 
observed in calendar year 2000 and outcomes (DN/CRF) were identiﬁ ed between
January 1, 2001 and September 30, 2001. Patients who received any diagnosis of renal
disease (DN/CRF) before 2001 and were on both ACEI and ARB were excluded. 
A Cox proportional hazards model was employed to examine the association
between time to DN/CRF diagnosis and exposure to ACEI or ARB. The confounders 
adjusted in the model included patient socio-demographics, co-morbidities, and co-
medications. RESULTS: The ﬁ nal cohort consisted of 427,124 patients with a mean 
age of 76 years. Majority of the patients were males (97.76%), whites (83.83%), in 
the age group of 76 to 85 years (48.32%). Cardiovascular comorbidities were 
common, with almost 80% of patients having hypertension, ischemic heart disease 
(IHD; 34%), and Chronic Heart Failure (CHF; 26%). A total of 2.76% of the 
patients from the ﬁ nal cohort developed DN/CRF. Multivariable analysis revealed that 
exposure to ACEI and ARBs is associated with increased risk of DN/CRF by 42% 
(95% CI 1.354–1.481) and 51% (95% CI 1.37–1.656) respectively. Many co-morbid
conditions (Hypertension, IHD, CHF) and all the co-medications adjusted in the 
model were signiﬁ cantly associated with increased risk of DN/CRF, with most pro-
minent association found in patients using insulin, antihypertensives, and diuretics.
CONCLUSIONS: Our study indicates that the use of agents that inhibit Renin-
Angiotensin-Aldosterone System (RAAS) do not prevent the development of DN/CRF.
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Results must be interpreted with caution, and further studies are needed to carefully 
address limitations and improve upon these initial results.
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RISK FACTORS FOR DEMENTIA IN ELDERLY PATIENTS WITH
DIABETES MELLITUS
Parikh NM1, Morgan R2, Kunik M3, Schulz P4, Chen H5, Aparasu R5, Yadav R5, Johnson M5
1Analysis Group, Inc., Boston, MA, USA, 2University of Texas, Houston, TX, USA, 3Center of 
Quality of Care and Utilization Studies, Veterans Affairs Medical Center, Houston, TX, USA, 
4Baylor Neurology, Houston, TX, USA, 5University of Houston, Houston, TX, USA
OBJECTIVES: Various factors may interact with Diabetes Mellitus (DM) to increase 
the risk of dementia. This study examined socio-demographic factors, the use of dia-
betes-speciﬁ c drugs and the duration of DM as risk factors for dementia in elderly
DM patients who are eligible to receive care at Veterans Health Administration.
METHODS: This was a retrospective study on a national cohort of US veterans. 
Incident DM elderly (q65 years) identiﬁ ed between October 1, 1996 and December 
31, 2000 in the VA records or between January 1, 1999 and December 31, 2000 in 
the VA-Medicare merged claims ﬁ les were included for the ﬁ nal analysis. The period 
prevalence of diabetes-speciﬁ c drugs was determined in Calendar Year (CY) 2000. The 
time to the incidence of dementia was assessed from CY2001 to CY2002. A multivari-
able Cox regression model was used to estimate the adjusted relative risk of dementia
for various predictors. RESULTS: A total of 377,838 patients were included in the
ﬁ nal analysis. Age was a major risk factor for dementia: patients 75–85 years of age, 
HR 2.09, 95% CI 2.02–2.17; patients 85 years and older, HR 3.47, 95% CI 3.27–
3.67. Compared to whites, African Americans had a higher risk of dementia (1.22,
1.16–1.27). People from the southern region of the U.S. had a higher risk of dementia 
compared to other regions. Oral hypoglycemic agent use was associated with a higher
risk of dementia (1.34, 1.29–1.39). The use of HMG-CoA reductase inhibitors was 
associated with a reduced risk of dementia (0.88, 0.85–0.91). Insulin was not associ-
ated with dementia (1.02, 0.98–1.07). The duration of diabetes was an important risk
factor for dementia. CONCLUSIONS: This exploratory study provides an important
insight into the risk factors for dementia in a large population of DM patients. Addi-
tional studies should examine the process and outcomes for patients with these 
important chronic disease conditions.
PDB13
PATTERNS AND POTENTIAL RISKS OF CO-PRESCRIBING 
ANTIHYPERGLYCEMICS AND SILYMARIN: A TAIWANESE
POPULATION-BASED STUDY
Chan AL1, Leung HW2, Chien TW3
1Chi-Mei Medical Center, Taianan, Taiwan, 2Chi-Mei Medical Center, Tainan, Taiwan, 3Chi-Mei 
Medical Center, Yung Kang, Tainan, Taiwan
OBJECTIVES: The aim of this study was to analyze trends and potential risks of 
combined use of silymarin and hypoglycemic drugs in a Taiwanese population. 
METHODS: Data for this retrospective and descriptive population-based study were
retrieved from the Taiwan National Health Insurance Research Database representing 
200,000 sampling beneﬁ ciaries enrolled in the program in the year 2000. The prescrip-
tion details of ambulatory care orders were retrieved for 2000 to 2006. The extent of 
co-prescription of silymarin and hypoglycemic drugs and associations with patient
characteristics, hospital type, and co-morbid chronic diseases were assessed, including 
an analysis using the many-faceted Rasch model. RESULTS: Silymarin prescriptions 
increased from 0.17% (860/515765) in 2000 to 0.76% (2335/309053) in 2006. Sily-
marin combined with hypoglycemic drugs was mostly prescribed to patients 60 years
or older. Among this group, the percentage of prescriptions with silymarin alone
increased about four-fold, from 245 in 2000 to 1022 in 2006. The number of co-pre-
scriptions in the same age group also increased in the same period from 11 (15.49%) 
to 206 (58.8%). Most prescriptions were prescribed for 28 days. Of the combined
prescriptions, 42% were prescribed at the same ambulatory care visit. Co-prescription
of silymarin and hypoglycemic drugs correlated with patient characteristics, physician
specialty, antidiabetic type, and other confounders. CONCLUSIONS: There was a
trend to increase of co-prescription of silymarin and hypoglycemic drugs in Taiwan’s 
elderly population from 2000 to 2006. Physicians should take particular care in 
adjusting the dose of hypoglycemic drugs when prescribing these drugs and silymarin 
concurrently in this age group.
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FORECASTING THE NUMBER OF DIABETIC PATIENTS IN THE
UNITED STATES THROUGH 2025
Baser O1, Wang L2
1University of Michigan and STATinMED Research, Ann Arbor, MI, USA, 2STATinMED
Research, Ann Arbor, MI, USA
OBJECTIVES: To project the number of people with diagnosed diabetes in the United
States through 2025, accounting for changing demography and diabetes prevalence
rates. METHODS: We combined age, sex, and race speciﬁ c diabetes prevalence rates
– predicted from the 1980–1998 trends in prevalence data from the National Health 
Interview Survey – with the population projections derived from MEPS. Sensitivity 
analysis was performed by varying both population projections and prevalence rates.
RESULTS: Populations of the number of people with diabetes will rise to almost 18
million in 2025. The largest increases in the number of people with diabetes are likely 
to occur in the oldest age category. The highest growth will be among black males 
whereas the lowest increase will be in the white females category. Twenty percent of 
the overall projected growth will be due to population growth, 35% to an increase in 
prevalence rate, and 45% to changes in demographic compositions. CONCLUSIONS:
This paper shows the projection of dramatic increase of the diabetic population in the 
United States by 2025. Worldwide surveillance of diabetes is a necessary ﬁ rst step 
toward its prevention and control.
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UTILIZATION PATTERNS AND HYPOGLYCEMIA IN PATIENTS
WITH TYPE-2 DIABETES ON CONCOMITANT EXENATIDE AND
LONG-ACTING INSULIN THERAPY
Wade R1, Quimbo RA2, Fabunmi R3, Blickensderfer AL3, Pawaskar MD4, Misurski D4
1HealthCore, Inc., Wilmington, DC, USA, 2HealthCore, Inc., Wilmington, DE, USA, 3Amylin
Pharmaceuticals, Inc., San Diego, CA, USA, 4Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To examine utilization patterns and hypoglycemia in patients with
type-2 diabetes mellitus (T2DM) receiving concomitant exenatide and long-acting 
insulin therapy over 6 months. METHODS: A retrospective analysis was performed 
using claims data (January 1, 2004 to March 31, 2008) from a large US prescription 
database. Adult patients with T2DM and no claim for exenatide (index drug) in the
previous 12 months were included. At least 12 months pre-index and q6 months 
post-index continuous eligibility were required. Concomitant long-acting insulin use 
was deﬁ ned as a claim for NPH, insulin glargine or insulin detemir 100 days pre-index 
to 15 days post-index. Therapy discontinuation was deﬁ ned as a 60 day gap between 
prescription claims. Hypoglycemic events were identiﬁ ed by ICD-9 codes 250.8, 
251.0, 251.1, and 251.2. Hypoglycemia generating a claim using these codes is gener-
ally severe. RESULTS: Concomitant exenatide and long-acting insulin use was identi-
ﬁ ed in 2082 patients. Of these, 38% discontinued both therapies, 15% discontinued 
exenatide but remained on long-acting insulin, 24% discontinued long-acting insulin 
but remained on exenatide and 23% continued both therapies. There were no differ-
ences in age, gender or Deyo-Charleson comorbidity index score among cohorts.
Patients who discontinued exenatide and remained on long acting insulin had a higher 
mean rate of hypoglycemia (0.10 o 1.01 events/patient/6-months), compared to 
patients who discontinued long-acting insulin but remained on exenatide (0.02 o
0.20), discontinued both therapies (0.04 o 0.37) or continued both therapies (0.03 o
0.26; p  0.0001 across groups). Insufﬁ cient pre- and post-A1C values were available 
for an analysis of this endpoint. CONCLUSIONS: Patients remaining on concomitant
exenatide and long-acting insulin did not experience more hypoglycemic events than 
patients who remained on either drug alone. However, patients discontinuing exena-
tide but remaining on long-acting insulin experienced signiﬁ cantly more hypoglycemic 
events. The increase in hypoglycemic events may have been due to an increase in basal 
insulin dose and/or the addition of other insulin therapy.
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REPLICATION AND VALIDATION OF THE QUANTIFICATION OF
THE RELATIONSHIP BETWEEN PHARMACOLOGIC INTERVENTION, 
REDUCTIONS IN HBA1C AND REDUCTIONS IN COMPLICATIONS: 
ITS APPLICATION IN QUANTIFYING THE BENEFITS OF ADDING
COLESEVELAM HYDROCHLORIDE TO METFORMIN IN TYPE-2
DIABETICS
Simons WR1, Hagan MA2
1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Daiichi Sankyo, Inc., 
Wayne, NJ, USA
OBJECTIVES: Quantify the reductions in diabetic related complications associated 
with the addition of colesevelam hydrochloride to metformin in patients with type-2 
diabetes who have not achieved optimal control. METHODS: The quantiﬁ cation of 
the effects of pharmacologic intervention on glycaemic control in type-2 diabetics and
the quantiﬁ cation that improved glycaemic control reduces the risk of diabetic-related
complications was measured in the UK, Germany and the USA using Generalized
Estimating Equations (GEE) on longitudinal data. The three models quantiﬁ ed that 
pharmacologic intervention reduced HbA1c by 0.99%, 0.92% and 0.89%, respec-
tively, (P  0.01). The second set of models quantiﬁ ed that a 1% reduction in HbA1c 
reduced the rate of complications by 0.388%, 0.414% and 0.436% (P  0.01). Using
these validated equations, the efﬁ cacy data from a clinical trial comparing the addition
of colesevelam hydrochloride to metformin versus metformin alone in type 2 diabetic 
patients who lack optimal control despite treatment was converted into reductions in
the onset new diabetic-related complications. 5000 bootstrap samples of 100 patients 
from each treatment group were replicated to measure and minimize bias. RESULTS:
In the ﬁ rst year, the addition of colesevelam to metformin reduces the number of dia-
betic related complications by 10,757 in 100,000 type-2 diabetics who lack glycaemic 
control despite treatment. The most prevalent of those complications are manifesta-
tions of neurological dysfunction (0.0166), disorders of the peripheral circulation
(0.0170) and ischemic heart disease (0.0178). Treatment with coleselevam in these 
patients who had not achieved optimal control reduced those events by 1790 neuro-
logical disorders, 1829 peripheral circulatory disorders and 1917 new cases of isch-
emic heart disease. The number of events avoided by year two and three accrued to 
18,173 and 27,505 per 100,000 patients. CONCLUSIONS: Effective treatment by 
adding colesevelam to metformin quantiﬁ ably reduces HbA1c and complications in 
patients who have not achieved control.
